Palisade Bio
Palisade Bio reported revenue of $0 million in fiscal 2025. The diluted share count rose 3830.2%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Palisade Bio does
Palisade Bio is a clinical-stage biopharmaceutical company, meaning it tests medicines in people and has none approved for sale. It is developing once-daily pills that block an enzyme called PDE4, which plays a role in inflammation and scarring. The pills are prodrugs: they stay inactive until bacteria in the lower intestine switch them on, so the drug acts mainly in the colon and ends of the small intestine.
Its lead candidate, PALI-2108, is being developed for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company is working toward a Phase 2 study in ulcerative colitis and early studies in fibrostenotic Crohn's disease, which involves scarring of the intestine. It is also building a biomarker approach to pick patients more likely to respond.
Palisade says it may seek partners, buy rights to new candidates or sell its own. It holds the patent rights to PALI-2108 under a license agreement with Giiant.
Its biggest risks, as it describes them
- Its business depends on one lead candidate, PALI-2108, which must succeed in trials and win approval.
- It relies on a license agreement with Giiant for the patents on PALI-2108.
- It depends on two qualified suppliers for the active ingredient used in its trials.
- It needs to keep its senior managers and scientists.
Income statement
Palisade Bio lost money in fiscal 2025: a net loss of $17 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 10 | 12 | 12 | 10 | 133 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −10 | −12 | −12 | −10 | −133 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −17.4x | −1,209.3x | −871.3x | −1,238.2x | −1,805.6x |
| Current ratio | 4.6x | 4.9x | 5.2x | 3.2x | 28.9x |
| Quick ratio | 4.6x | 4.9x | 5.2x | 3.2x | 28.9x |
Cash flow
Projections
Project Palisade Bio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $318,135 of Palisade Bio shares on the open market, and 2 insiders sold $420,525.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Robert Baltera Jr.Director | Bought | 50,000 | $1.01 | $50,285 | Form 4 |
| Jul 9, 2026 | Robert Baltera Jr.Director | Bought | 25,000 | $1.96 | $49,000 | Form 4 |
| Jul 8, 2026 | Robert Baltera Jr.Director | Bought | 20,000 | $1.99 | $39,800 | Form 4 |
| Jul 7, 2026 | John David FinleyCEO, CFO, Director | Sold | 146,798 | $2.07 | $303,872 | Form 4 |
| Jul 7, 2026 | Mitchell Lawrence JonesChief Medical Officer | Sold | 51,880 | $2.05 | $106,354 | Form 4 |
| Jul 7, 2026 | Robert Baltera Jr.Director | Bought | 30,000 | $2.03 | $60,900 | Form 4 |
| Jul 6, 2026 | Robert Baltera Jr.Director | Bought | 20,000 | $2.05 | $41,000 | Form 4 |
| Jul 2, 2026 | Robert Baltera Jr.Director | Bought | 10,000 | $1.98 | $19,800 | Form 4 |
| Jul 1, 2026 | Robert Baltera Jr.Director | Bought | 20,000 | $1.98 | $39,600 | Form 4 |
| Feb 12, 2026 | John David FinleyCEO, CFO, Director | Sold | 3,896 | $1.75 | $6,818 | Form 4 |
| Feb 12, 2026 | Mitchell Lawrence JonesChief Medical Officer | Sold | 1,989 | $1.75 | $3,481 | Form 4 |
| Jan 16, 2026 | Donald Allen WilliamsDirector | Bought | 5,000 | $1.67 | $8,350 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 8 | 1 of 8 | 2 of 8 |
| Rule of 40 | — | — | — |
| Altman Z'' | 31.29 | 38.24 | — |
| Accruals ratio | −7.8% | −18.0% | −8.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | 4 of 8 | 1 of 8 | 2 of 8 |
Compare
Put Palisade Bio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Palisade Bio | FY25 | — | — | — | — | — | 2 | |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
| AbCellera Biologics | FY25 | 160.6% | −289.0% | −231.7% | — | — | — | Compare |
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 |
| Revenue growth | 56.0% | 1,500.4% | 0.0% | −94.1% | −12.2% | — | — | — | −100.0% | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 13 | 8 | 4 | 4 | 2 | 2 | 6 | 7 | 16 | 10 |
| Operating income | −21 | −13 | −8 | −9 | −9 | −42 | −16 | −13 | −15 | −18 |
| Net income | −21 | −16 | −5 | −8 | −10 | −27 | −14 | −12 | −14 | −17 |
| Diluted EPS (US$) | −9,487.50 | −4,500.00 | −28,275.00 | −14,250.00 | −2,790.00 | −2,546.10 | −247.95 | −27.01 | −10.19 | −0.30 |
| Diluted shares (millions) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 56 |
| Cash flow | ||||||||||
| Cash from operations | −16 | −13 | −8 | −7 | −5 | −15 | −13 | −11 | −12 | −11 |
| Capital expenditure | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | — |
| Free cash flow | −16 | −13 | −8 | — | −5 | −15 | −13 | −11 | −12 | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 4 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 20 | 12 | — | 5 | 1 | 10 | 12 | 12 | 10 | 133 |
| Debt incl. finance leases | — | — | — | — | 1 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 23 | 14 | 8 | 7 | 3 | 12 | 16 | 14 | 11 | 134 |
| Total liabilities | 11 | 5 | 2 | 2 | 10 | 5 | 3 | 3 | 3 | 5 |
| Shareholders' equity | 11 | 8 | 6 | −8 | −17 | 7 | 12 | 11 | 8 | 129 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −127,027.2% | −5,118.1% | −3,176.7% | −56,071.8% | −68,764.8% | — | — | −5,228.0% | — | — |
| Net margin | −129,721.9% | −6,025.4% | −1,894.1% | −54,252.6% | −76,346.1% | — | — | −4,920.0% | — | — |
| Free cash flow margin | −96,726.6% | −5,164.4% | −2,959.3% | — | −35,310.7% | — | — | −4,454.8% | — | — |
| Rule of 40 (growth + FCF margin) | −96,670.6% | −3,664.1% | −2,959.3% | — | −35,322.8% | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −258.6% | −157.9% | −67.6% | — | — | — | −143.7% | −103.4% | −153.6% | −24.5% |
| Return on assets | −112.2% | −85.9% | −45.7% | −117.1% | −215.0% | −342.8% | −100.9% | −82.5% | −115.8% | −23.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |